Geron Corporation
Geron Corporation (GERN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GERN · as of Sep 30, 2025
Ownership Breakdown
267
Institutional Holders
▲ 3 vs Q2
$695.04M
Total Inst. Value
▼ $30.36M vs Q2
641.52M
Shares Outstanding
freeFloat 83.51%
507.09M
13F Shares Held
▼ 7.37M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GERN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 60.38M | 9.06% | 9.06% | $82.72B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 46.61M | 7.00% | 7.00% | $63.85B | Nov 12, 2025 | ▼ 3.42M |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 41.10M | 6.17% | 6.17% | $56.30B | Nov 14, 2025 | ▼ 1.90M |
VANGUARD GROUP INC pharmaceutical preparations | 34.42M | 5.17% | 5.17% | $47.16B | Nov 7, 2025 | ▼ 1.19M |
VIVO CAPITAL, LLC pharmaceutical preparations | 27.23M | 4.09% | 4.09% | $37.30B | Nov 14, 2025 | — held |
STATE STREET CORP pharmaceutical preparations | 26.62M | 4.00% | 4.00% | $36.47B | Nov 14, 2025 | ▲ 2.99M |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 21.31M | 3.20% | 3.20% | $29.19B | Nov 14, 2025 | ▲ 11.49M |
SOLEUS CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 17.29M | 2.60% | 2.60% | $23.69B | Nov 14, 2025 | ▲ 1.15M |
VESTAL POINT CAPITAL, LP pharmaceutical preparations | 17.23M | 2.59% | 2.59% | $23.60B | Nov 14, 2025 | ▼ 6.55M |
CITADEL ADVISORS LLC pharmaceutical preparations | 15.71M | 2.36% | 2.36% | $21.52B | Nov 14, 2025 | ▲ 3.67M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
15
Increased
+38.64M shares5
New Positions
first time holders24
Decreased
−35.71M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.93M
+38.64M / −35.71M
Net new holders
-4
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GERN insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Spiegel Robert J. director | May 20, 2026 | Award | 220,000 | $1.26 | $277.2K | 220.0K | Form 4 ↗ |
O'Farrell Elizabeth G. director | May 20, 2026 | Award | 220,000 | $1.26 | $277.2K | 220.0K | Form 4 ↗ |
Molineaux Susan director | May 20, 2026 | Award | 220,000 | $1.26 | $277.2K | 220.0K | Form 4 ↗ |
McDonald John F director | May 20, 2026 | Award | 220,000 | $1.26 | $277.2K | 220.0K | Form 4 ↗ |
Bir Dawn Carter director | May 20, 2026 | Award | 220,000 | $1.26 | $277.2K | 220.0K | Form 4 ↗ |
Williams Timothy EVP and Chief Legal Officer | Apr 13, 2026 | Award | 2,500,000 | $1.73 | $4.33M | 2.50M | Form 4 ↗ |
Spiegel Robert J. director | Mar 31, 2026 | Award | 5,243 | $1.49 | $7.8K | 199.7K | Form 4 ↗ |
Chinoporos Constantine director | Mar 25, 2026 | Award | 270,000 | $1.57 | $423.9K | 270.0K | Form 4 ↗ |
Andrews Patricia S director | Mar 25, 2026 | Award | 270,000 | $1.57 | $423.9K | 270.0K | Form 4 ↗ |
Eid Joseph EVP, R&D; Chief Medical Office | Feb 17, 2026 | Award | 2,220,000 | $1.80 | $4.00M | 2.22M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Geron Corporation (GERN) is primarily owned by institutional investors, who hold approximately 79.0% of total shares outstanding. Company insiders own approximately 16.49%, while retail and public investors account for the remaining 4.46%.
The largest institutional shareholder of Geron Corporation is RA CAPITAL MANAGEMENT, L.P., holding approximately 60.38 million shares — equal to 9.06% of outstanding shares — as of September 30, 2025.
A total of 267 institutional investors currently hold GERN stock, with a combined institutional value of approximately $695,035,099 as of the most recent 13F filing period.
Frequently asked questions
GERN ownershipGeron Corporation (GERN) is primarily owned by institutional investors, who hold approximately 79.0% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 9.06% stake. Company insiders hold 16.49%. Data sourced from SEC Form 13F as of September 30, 2025.